Biotech and Pharma Industry News | BioPharma Dive
WEBBioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Denali, fresh off study setback, gets $500M lift | BioPharma Dive
WEBFeb 27, 2024 · Neurodegenerative disease drugmaker Denali Therapeutics announced Tuesday it is raising an expected $500 million through a private financing deal with existing investors. Through the deal, the company will sell over 3 million shares of its common stock at $17.07 apiece and issue warrants for more than 26 …
Biotech stock fundings headed for best quarter in 3 years, Jefferies ...
WEBMar 11, 2024 · Data the firm published over the weekend show biotech is on pace to post its highest quarterly total in three years, potentially exceeding the $11 billion companies raised in follow-on stock offerings in the first quarter of 2021. The average size of those financings increased from $167 million in January to $191 million in February, the report ...
Biotech M&A is on the upswing. Here are the latest deals.
WEBAug 13, 2024 · BioPharma Dive is tracking M&A activity below. The database, which shows drugmaker buyouts that have happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Click on an acquiring company to pull up more information, and scroll to the bottom of the page to read how this information was ...
FDA advisers offer unanimous support to second Bluebird gene …
WEBPublished June 10, 2022. For the second time in two days, advisers to the Food and Drug Administration gave their unanimous support to an experimental gene therapy for a rare inherited disease, agreeing its benefits outweigh its risks. The expert panel voted 13-0 in support of the treatment, developed by Bluebird bio for the blood condition ...
A decade later, biotech’s CRISPR revolution is still going strong
WEBOct 11, 2023 · A cell and an injection needle are projected onto a screen during a CRISPR/Cas9 experiment in Berlin, Germany, on May 22, 2018. A research paper published a decade ago touched off a biomedical revolution that has made careers, spawned companies and drawn billions of dollars of investment. By the end of the year, the gene editing technology that ...
Intra-Cellular approval keeps focus on FDA's neuroscience review ...
WEBDec 23, 2019 · The Food and Drug Administration on Monday approved Intra-Cellular’s lumateperone as a treatment for adults with schizophrenia, a decision that supports speculation the agency is taking a more flexible approach when evaluating neuroscience medicines. Lumateperone, which will be sold as Caplyta, showed conflicting results …
Meso Scale Discovery (MSD): An immunoassay platform with …
WEBFeb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high precision. . Furthermore, MSD has simpler protocols, reduced ...
Radius, maker of bone and cancer drugs, to be bought in take …
WEBJun 23, 2022 · Radius Health, a maker of bone and cancer drugs, has agreed to be taken private in an acquisition worth up to $890 million, announcing Thursday a deal to merge with a subsidiary of two investment firms. The firms, Gurnet Point Capital and Patient Square Capital, will pay $10 per Radius share as well as an additional $1 per share should sales of Radius’ principal drug, an osteoporosis ...
Biotech IPOs are the industry’s lifeblood. Track how they’re …
WEB4 days ago · IPO activity reached a peak in 2021, when more than 100 biotechs priced an initial offering and together raised nearly $15 billion. But that momentum came to a halt as 2021 turned to 2022, and stock prices of newly public companies plummeted amid a sector-wide downturn. The pace of IPOs stalled and, last year, only 19 drugmakers priced initial ...